Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Sales and Divestitures (2016 - 2025)

Amphastar Pharmaceuticals has reported Gains from Sales and Divestitures over the past 13 years, most recently at $372602.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $372602.0 for Q4 2025, down 4.17% from a year ago — trailing twelve months through Dec 2025 was $372602.0 (down 4.17% YoY), and the annual figure for FY2025 was $372602.0, down 4.17%.
  • Gains from Sales and Divestitures for Q4 2025 was $372602.0 at Amphastar Pharmaceuticals, roughly flat from $372218.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for AMPH hit a ceiling of $493718.0 in Q4 2021 and a floor of $338280.0 in Q1 2025.
  • Median Gains from Sales and Divestitures over the past 5 years was $416990.0 (2021), compared with a mean of $419789.0.
  • Biggest five-year swings in Gains from Sales and Divestitures: dropped 21.39% in 2021 and later grew 0.01% in 2022.
  • Amphastar Pharmaceuticals' Gains from Sales and Divestitures stood at $493718.0 in 2021, then decreased by 3.17% to $478068.0 in 2022, then dropped by 7.86% to $440484.0 in 2023, then decreased by 11.73% to $388816.0 in 2024, then dropped by 4.17% to $372602.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $372602.0 (Q4 2025), $372218.0 (Q3 2025), and $367827.0 (Q2 2025) per Business Quant data.